Megace Caution

Issue #76 of AIDS TREATMENT NEWS announced recruitment for a study of Megace (megestrol acetate) through the San Francisco County Community Consortium. The goal of the trial is to determine whether Megace, a prescription drug used to treat breast cancer, also has the potential to enhance appetite and weight gain in people with ARC who are experiencing cachexia, or wasting syndrome.

James Kahn, M.D., the principal investigator of this study was notified earlier this month by the manufacturer, Bristol-Myers, that one participant in another Megace study had developed a severe rash covering most of his body after eight days of Megace, 1200 mg each day. The rash was later diagnosed as Stevens-Johnson Syndrome. It was treated with benadryl and steroids and resolved slowly. Because the participant had a diagnosis of AIDS and had been receiving other medications, there is not a conclusive link between the rash and Megace. Nevertheless, Dr. Kahn felt that we should caution people on Megace to be aware of any allergic reactions (which must be seen immediately by a physician). Dr. Kahn can be reached at 415/821-5531.

The Consortium trial is still open, and as before, all participants will be closely monitored by nutritionists, nurses and physicians. Those interested can call Helen Mudie at 415/821-5495 or Ann Conroy at 565-6649.

**********